Submitted Orals

Wednesday 16th of April 2014
14:30-15:30
SO11, 1.5 hours

Chair: Gavin Brooks (UK)

Meeting room 211

14.30 – 14.45      Safety and efficacy results of a phase IV safety-monitoring study of icotinib in treating advanced non-small cell lung cancer (15 min)
(WE-24-01) Lieming Ding (China)

14.45 – 15.00      FGF21 maintains glucose homeostasis by mediating the crosstalk between liver and brain during prolonged fasting (15 min)
(WE-24-02) Qingning Liang (Hong Kong)

15.00 – 15.15     Immunomodulators and/or probiotics as adjunctive therapy for eradication of H.Pylori and improvement of immune system in peptic ulcer disease
(WE-24-02) Kughan Govinden (Russia)

15.15 – 15.30      Population pharmacokinetics of imatinib mesylate in nigerian patients with chronic myeloid leukemia
(WE-24-03) Babatunde Adeagbo (Nigeria)